Multiple antioxidants in the prevention and treatment of neurodegenerative disease: Analysis of biologic rationale

Current Opinion in Neurology

Volumn 12, Issue 6, 1999, Pages 761-770

  Prasad, Kedar N ^a   Cole, William C ^a   Hovland, Alicia R ^a   Prasad, K Che ^b   Nahreini, Piruz ^a   Kumar, Bipin ^a   Edwards Prasad, Judith ^a   Andreatta, Cynthia P ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; FREE RADICAL; LEVODOPA; NEUROTOXIN; RETINOL; SELEGILINE; TOCOPHEROL;

AGING; ALZHEIMER DISEASE; CELL MEMBRANE; CELL NUCLEUS; CLINICAL TRIAL; DATA ANALYSIS; HUMAN; MITOCHONDRION; NERVE DEGENERATION; NONHUMAN; ONSET AGE; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN MODIFICATION; REVIEW; RISK FACTOR;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; HUMANS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 0033401128     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199912000-00017     Document Type: Review

References (49)

1. Olanow CW. Neurodegeneration and neuroprotection in Parkinson's disease. Academic Press, 1996.
2. Schapira AH. Pathogenesis of Parkinson's disease. Baillieres Clin Neurol 1997; 6:15-36.
3. Bowling A, Beal M. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 1995; 56:1151-1171.
4. Prasad K, Hovland A, Cole W, Prasad K, Nahreini P, Prasad J, Andreatta C. Multiple antioxidants in the prevention and treatment of Alzheimer's disease: analysis of biological rationale. Clin Neuropharmacol 1999 (in press). • This paper proposes that epigenetic components rather than nuclear genes of neurons are the primary targets for the actions of neurotoxins that lead to Alzheimer's disease.
5. Prasad K, Cole W, Kumar B. Multiple antioxidants in the prevention and treatment of Parkinson's disease. J Am Coll Nutr 1999 (in press). • This paper proposes that epigenetic components rather than nuclear genes of neurons are the primary targets for the actions of neurotoxins that lead to Parkinson's disease.
6. Langston J. Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Ann Neurol 1998; 44:545-552.
7. Rogers L, Lue L-F, Brachova L, Webster S, Schultz J. Inflammation as a response and a cause of Alzheimer's pathophysiology. Dementia 1995; 9:133-138.
8. Andersen K, Launer L, Ott A, Hoes A, Bretler M, Hofman A. Do non-steroidal antiinflammatory drugs decrease the risk of Alzheimer's disease? Neurol 1995; 45.
9. Braak H, de Vos RA, Jansen EN, Bratzke H, Braak E. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog Brain Res 1998; 117:267-285. • This article describes neuropathologic features of Alzheimer's disease and Parkinson's disease in a comparative manner.
10. Cassarino DS, Bennett JP Jr. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Rev 1999; 29:1-25.
11. Egensperger R, Kosel S, Schnopp NM, Mehraein P, Graeber MB. Association of the mitochondrial tRNA(A4336G) mutation with Alzheimer's and Parkinson's diseases. Neuropathol Appl Neurobiol 1997; 23:315-321.
12. Schulz JB, Matthews RT, Klockgether T, Dichgans J, Beal MF. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol Cell Biochem 1997; 174:193-197.
13. Wei YH. Mitochondrial DNA mutations and oxidative damage in aging and diseases: an emerging paradigm of gerontology and medicine. Proc Natl Sci Council Republic of China B Life Sci 1998; 22:55-67.
14. Wei YH, Lu CY, Lee HC, Pang CY, Ma YS. Oxidative damage and mutation to mitochondrial DNA and age-dependent decline of mitochondrial respiratory function. Ann N Y Acad Sci 1998; 854:155-170.
15. Keller JN, Mattson MP. Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Rev Neurosci 1998; 9:105-116.
16. Kruman I, Bruce-Keller AJ, Bredesen D, Waeg G, Mattson MP. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci 1997; 17:5089-5100.
17. Storey E, Cappai R. The amyloid precursor protein of Alzheimer's disease and the Abeta peptide. Neuropathol Appl Neurobiol 1999; 25:81-97.
18. Fukuda H, Shimizu T, Nakajima M, Mori H, Shirasawa T. Synthesis, aggregation, and neurotoxicity of the Alzheimer's Abeta 1-42 amyloid peptide and its isoaspartyl isomers. Bioorganic Med Chem Lett 1999; 9:953-956.
19. Trojanowski JQ, Goedert M, Iwatsubo T, Lee VM. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differentiation 1998; 5:832-837.
20. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392:605-608.
21. Martin JB. Molecular basis of the neurodegenerative disorders. N Engl J Med 1999; 340:1970-1980. •• This is an en excellent review on the genetic bases of neurodegenerative diseases in a comparative manner.
22. Marx J. New gene tied to common form of Alzheimer's [news]. Science 1998; 281:507-509.
23. McConnell LM, Koenig BA, Greely HT, Raffin TA. Genetic testing and Alzheimer disease: has the time come? Alzheimer Disease Working Group of the Stanford Program in Genomics, Ethics & Society. Nature Med 1998: 4:757-759.
24. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nature Genet 1998; 19:357-360.
25. Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, et al. A full genome scan for late onset Alzheimer's disease. Hum Mol Genet 1999; 8:237-245.
26. Polymeropoulos M, Lavedan C, Leroy E, Ide S, et al. Mutation in the χ-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-2047.
27. Zhou W, Hurlbert M, Schaack J, Prasad K, Freed C. Overexpression of human χ-synuclein increases dopamine neuron sensitivity to 6-hydroxydopamine. J Neurochem (submitted).
28. Cruts M, Van Broeckhoven C. Molecular genetics of Alzheimer's disease. Ann Med 1998; 30:560-565.
29. Rogaev EI, Sherrington R, Wu C, Levesque G, Liang Y, Rogaeva EA, et al. Analysis of the 5′ sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset Alzheimer disease. Genomics 1997; 40:415-424.
30. Dewji NN, Singer SJ. Genetic clues to Alzheimer's disease. Science 1996; 271:159-160.
31. Chiueh CC, Rauhala P. Free radicals and MPTP-induced selective destruction of substantia nigra compacta neurons. Adv Pharmacol (New York) 1998; 42:796-800.
32. Koppal T, Drake J, Yatin S, Jordan B, Varadarajan S, Bettenhausen L, Butterfield DA. Peroxynitrite-induced alterations in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's disease. J Neurochem 1999; 72:310-317.
33. Bondy SC, Kirstein S. The promotion of iron-induced generation of reactive oxygen species in nerve tissue by aluminum. Mole Chem Neuropathol 1996; 27:185-194.
34. Schipper HM, Cisse S, Stopa EG. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann Neurol 1995; 37:758-768.
35. Schapira AH. Oxidative stress and mitochondrial dysfunction in neurodegeneration. Curr Opin Neurology 1996; 9:260-264. • This is an excellent review on the role of oxidative stress in neurodegeneration.
36. Schubert D, Behl C, Lesley R, Brack A, Dargusch R, Sagara Y, Kimura H. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci USA 1995; 92:1989-1993.
37. Pappolla MA, Chyan YJ, Omar RA, Hsiao K, Perry G, Smith MA, Bozner P. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 1998; 152:871-877.
38. Calderon FH, Bonnefont A, Munoz FJ, Fernandez V, Videla LA, Inestrosa NC. PC12 and neuro 2a cells have different susceptibilities to acetylcholinesterase-amyloid complexes, amyloid25-35 fragment, glutamate, and hydrogen peroxide. J Neurosci Res 1999; 56:620-631.
39. Anonymous. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1993; 328:176-183.
40. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 1992; 32:S128-S132.
41. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. Acontrolled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336:1216-1222. •• This paper describes that a high dose of vitamin E and selegiline produces beneficial effects on cognitive function in moderate to advanced Alzheimer's disease patients.
42. Prasad K, Kumar A, Kochupillai M, Cole W. High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy. J Am Coll Nutr 1999; 18:13-25.
43. 10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 1997; 37:212-218.
44. Birkmayer JG. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. Ann Clin Lab Sci 1996; 26:1-9.
45. Prasad KN, La Rosa FG, Prasad JE. Prostaglandins act as neurotoxin for differentiated neuroblastoma cells in culture and increase levels of ubiquitin and beta-amyloid. In Vitro Cell Dev Biol Anim 1998; 34:265-274.
46. Prasad KN, Hovland AR, La Rosa FG, Hovland PG. Prostaglandins as putative neurotoxins in Alzheimer's disease. Proc Soc Exp Biol Med 1998; 219:120-125. • This article discusses experimental, epidemiologic, and clinical evidence in support of an hypothesis that prostaglandins are one of the extracellular signals that initiate neurodegeneration associated with Alzheimer's disease.
47. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C. Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease [see comments]. Neurol 1995; 45:51-55.
48. McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease [Letter]. Lancet 1990; 335:1037.
49. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurol 1993; 43:1609-1611.